What is RxSight's operating income?

RxSight's total operating income in 2025 was -$48.19 million, based on the following breakdown: Total Gross Profit: $103.01 million Total Operating Expenses: $151.20 million

RxSight (RXST) Financials

$5.61 0.00 (0.00%)

Closing price 07/2/2026 04:00 PM Eastern

Extended Trading

$5.62 +0.00 (+0.09%)

As of 07/2/2026 07:59 PM Eastern

Compare

Annual Income Statements for RxSight

This table shows RxSight's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2020	2021	2022	2023	2024	2025
Period end date	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Net Income / (Loss) Attributable to Common Shareholders	3.37	-59	-67	-49	-27	-39
Consolidated Net Income / (Loss)	28	-49	-67	-49	-27	-39
Net Income / (Loss) Continuing Operations	27	-59	-67	-49	-27	-39
Total Pre-Tax Income	28	-49	-67	-49	-27	-39
Total Operating Income	-35	-53	-63	-50	-37	-48
Total Gross Profit	1.71	4.52	21	54	99	103
Total Revenue	15	23	49	89	140	134
Operating Revenue	15	23	49	89	140	134
Total Cost of Revenue	13	18	28	35	41	31
Operating Cost of Revenue	13	18	28	35	41	31
Total Operating Expenses	37	57	85	104	136	151
Selling, General & Admin Expense	15	33	59	75	101	113
Research & Development Expense	22	24	26	29	34	39
Total Other Income / (Expense), net	63	-6.35	-3.43	1.50	9.45	9.31
Interest Expense	0.51	3.68	4.95	5.08	0.02	0.02
Interest & Investment Income	0.00	0.05	1.52	6.57	9.47	9.33
Income Tax Expense	0.06	0.01	0.01	0.02	0.05	0.07
Other Adjustments to Net Income / (Loss) Attributable to Common Shareholders)	-	-	-	-0.01	0.01	-0.02
Basic Earnings per Share	$0.91	($3.57)	($2.41)	($1.41)	($0.71)	($0.95)
Weighted Average Basic Shares Outstanding	3.71M	13.63M	27.66M	34.46M	38.87M	40.85M
Diluted Earnings per Share	$0.15	($3.57)	($2.41)	($1.41)	($0.71)	($0.95)
Weighted Average Diluted Shares Outstanding	5.53M	13.63M	27.66M	34.46M	38.87M	40.85M
Weighted Average Basic & Diluted Shares Outstanding	1.00	0.00	33.78M	36.99M	40.49M	41.27M

This table shows RxSight's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Period end date	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025	3/31/2026
Net Income / (Loss) Attributable to Common Shareholders	-12	-9.18	-9.10	-6.08	-6.34	-5.94	-8.19	-12	-9.82	-9.13	-16
Consolidated Net Income / (Loss)	-12	-9.18	-9.10	-6.08	-6.34	-5.94	-8.19	-12	-9.82	-9.15	-16
Net Income / (Loss) Continuing Operations	-12	-9.18	-9.10	-6.08	-6.34	-5.94	-8.19	-12	-9.82	-9.15	-16
Total Pre-Tax Income	-12	-9.20	-9.09	-6.06	-6.33	-5.93	-8.17	-12	-9.81	-9.15	-16
Total Operating Income	-13	-11	-11	-8.33	-9.23	-8.63	-11	-14	-12	-11	-18
Total Gross Profit	14	18	21	24	25	29	28	25	24	25	23
Total Revenue	22	29	30	35	35	40	38	34	30	33	31
Operating Revenue	22	29	30	35	35	40	38	34	30	33	31
Total Cost of Revenue	8.47	11	8.83	11	10	11	9.57	8.45	6.11	7.34	7.40
Operating Cost of Revenue	8.47	11	8.83	11	10	11	9.57	8.45	6.11	7.34	7.40
Total Operating Expenses	26	29	31	33	34	37	39	39	36	37	41
Selling, General & Admin Expense	19	21	23	24	26	28	29	29	27	28	32
Research & Development Expense	7.10	7.34	8.03	8.29	8.84	9.21	10	10	9.06	8.91	9.47
Total Other Income / (Expense), net	0.11	1.66	1.58	2.27	2.90	2.70	2.50	2.25	2.37	2.19	1.95
Interest Expense	1.64	0.00	0.01	0.01	0.01	0.00	0.01	0.01	0.00	0.00	0.00
Interest & Investment Income	1.75	1.66	1.59	2.28	2.91	2.71	2.51	2.25	2.38	2.19	1.95
Income Tax Expense	0.01	-0.02	0.01	0.02	0.01	0.01	0.02	0.03	0.01	0.01	0.01
Basic Earnings per Share	($0.35)	($0.24)	($0.25)	($0.16)	($0.16)	($0.14)	($0.20)	($0.29)	($0.24)	($0.22)	($0.38)
Weighted Average Basic Shares Outstanding	35.66M	34.46M	36.84M	38.46M	39.79M	38.87M	40.51M	40.74M	40.97M	40.85M	41.31M
Diluted Earnings per Share	($0.35)	($0.24)	($0.25)	($0.16)	($0.16)	($0.14)	($0.20)	($0.29)	($0.24)	($0.22)	($0.38)
Weighted Average Diluted Shares Outstanding	35.66M	34.46M	36.84M	38.46M	39.79M	38.87M	40.51M	40.74M	40.97M	40.85M	41.31M
Weighted Average Basic & Diluted Shares Outstanding	35.86M	36.99M	37.20M	39.68M	40.30M	40.49M	40.64M	40.92M	41.12M	41.27M	41.40M

This table details how cash moves in and out of RxSight's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2020	2021	2022	2023	2024	2025
Period end date	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Net Change in Cash & Equivalents	5.63	11	-13	-2.19	7.05	3.24
Net Cash From Operating Activities	-35	-45	-59	-42	-17	-16
Net Cash From Continuing Operating Activities	-35	-39	-59	-42	-17	-16
Net Income / (Loss) Continuing Operations	28	-49	-67	-49	-27	-39
Consolidated Net Income / (Loss)	28	-49	-67	-49	-27	-39
Depreciation Expense	3.85	3.98	3.88	4.08	3.58	3.27
Amortization Expense	-0.20	0.48	-0.72	-5.84	-8.98	-8.52
Non-Cash Adjustments To Reconcile Net Income	-59	7.64	12	18	25	34
Changes in Operating Assets and Liabilities, net	-7.85	-2.68	-7.41	-8.91	-9.16	-4.89
Net Cash From Investing Activities	16	-82	40	-22	-99	17
Net Cash From Continuing Investing Activities	16	-82	40	-22	-99	17
Purchase of Property, Plant & Equipment	-2.54	-1.94	-2.39	-4.81	-5.44	-3.83
Purchase of Investments	-98	-160	-213	-272	-337	-239
Sale and/or Maturity of Investments	116	80	255	255	243	260
Net Cash From Financing Activities	25	137	6.33	62	123	1.86
Net Cash From Continuing Financing Activities	25	18	6.33	62	123	1.86
Repayment of Debt	-0.69	-0.13	-0.15	-62	0.00	0.00
Repurchase of Common Equity	0.00	0.00	-0.59	-0.62	-0.77	0.00
Issuance of Debt	25	16	0.00	20	0.00	0.00
Issuance of Common Equity	0.00	0.00	7.83	106	129	3.95
Other Financing Activities, net	0.87	2.32	-0.76	-1.58	-4.83	-2.09
Effect of Exchange Rate Changes	-	-0.01	-0.01	0.01	-0.01	0.00
Cash Interest Paid	0.43	3.19	4.26	3.46	0.00	0.00
Cash Income Taxes Paid	0.06	0.02	0.00	0.01	0.02	0.06

This table details how cash moves in and out of RxSight's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Period end date	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025	3/31/2026
Net Change in Cash & Equivalents	1.06	-0.17	23	-8.20	-7.73	0.02	11	12	-11	-9.68	-2.38
Net Cash From Operating Activities	-7.98	-8.30	-9.31	-4.03	0.65	-4.26	-8.83	-4.38	-1.19	-1.12	-11
Net Cash From Continuing Operating Activities	-7.98	-8.30	-9.31	-4.03	0.65	-4.29	-8.83	-4.38	-1.22	-1.12	-11
Net Income / (Loss) Continuing Operations	-12	-9.18	-9.10	-6.08	-6.34	-5.94	-8.19	-12	-9.82	-9.15	-16
Consolidated Net Income / (Loss)	-12	-9.18	-9.10	-6.08	-6.34	-5.94	-8.19	-12	-9.82	-9.15	-16
Depreciation Expense	1.08	1.05	1.12	0.81	1.13	0.52	0.78	0.79	0.85	0.85	0.83
Amortization Expense	-1.54	-1.54	-1.48	-2.07	-2.76	-2.62	-2.40	-2.14	-2.14	-1.83	-1.85
Non-Cash Adjustments To Reconcile Net Income	5.48	4.58	4.81	6.16	6.75	7.32	7.19	9.78	8.14	8.43	8.01
Changes in Operating Assets and Liabilities, net	-0.59	-3.21	-4.65	-2.86	1.87	-3.57	-6.21	-1.01	1.75	0.58	-1.99
Net Cash From Investing Activities	17	4.57	24	-116	-9.26	1.32	21	15	-9.00	-9.61	8.85
Net Cash From Continuing Investing Activities	17	4.57	24	-116	-9.26	1.32	21	15	-9.00	-9.61	8.85
Purchase of Property, Plant & Equipment	-0.65	-1.59	-1.97	-1.52	-1.10	-0.85	-0.58	-1.54	-0.58	-1.14	-0.76
Purchase of Investments	-72	-44	-48	-159	-77	-53	-39	-34	-68	-98	-100
Sale and/or Maturity of Investments	90	50	74	45	69	55	60	50	60	90	110
Net Cash From Financing Activities	-8.23	3.56	7.99	111	0.88	2.98	-0.74	2.07	-0.53	1.06	-0.34
Net Cash From Continuing Financing Activities	-8.23	3.56	7.99	111	0.88	2.98	-0.74	2.07	-0.53	1.06	-0.34
Repayment of Debt	-21	-0.01	0.00	-0.08	0.08	-	0.00	-	-	-	0.00
Repurchase of Common Equity	-0.05	0.03	0.00	-0.38	-0.39	-	0.00	-	-	-	0.00
Issuance of Debt	-	-	0.00	-	-	-	0.00	-	-	-	0.00
Issuance of Common Equity	14	3.58	10	112	3.84	2.99	0.70	2.07	0.13	1.06	0.14
Other Financing Activities, net	-1.12	-0.04	-2.16	-0.01	-2.65	-0.01	-1.43	-0.00	-0.66	0.01	-0.48
Effect of Exchange Rate Changes	-0.01	0.01	-0.00	-0.00	0.01	-0.01	0.01	0.01	-0.00	-0.02	0.00
Cash Interest Paid	0.23	0.00	0.01	0.01	0.01	0.01	0.00	-	-	-	0.00
Cash Income Taxes Paid	-	-0.00	0.00	0.02	0.00	-0.00	0.00	0.07	-	-0.01	0.00

This table presents RxSight's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2020	2021	2022	2023	2024	2025
Period end date	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Total Assets	101	193	150	183	319	312
Total Current Assets	82	176	135	168	294	287
Cash & Equivalents	14	24	12	9.69	17	20
Short-Term Investments	55	135	94	117	221	208
Accounts Receivable	2.87	4.86	11	20	30	23
Inventories, net	8.29	8.03	15	17	22	32
Prepaid Expenses	1.37	4.07	2.96	3.52	4.54	4.39
Plant, Property, & Equipment, net	13	11	10	11	12	13
Total Noncurrent Assets	5.89	5.21	5.47	3.30	12	11
Other Noncurrent Operating Assets	5.89	5.21	5.47	3.30	12	11
Total Liabilities & Shareholders' Equity	101	193	150	183	319	312
Total Liabilities	45	54	60	22	37	36
Total Current Liabilities	12	11	17	21	26	26
Accounts Payable	1.13	1.69	2.60	3.86	4.54	5.30
Accrued Expenses	4.17	7.86	13	15	20	20
Other Current Liabilities	6.29	1.53	1.97	1.80	0.97	1.16
Total Noncurrent Liabilities	33	43	43	1.29	11	9.88
Long-Term Debt	24	40	40	0.07	0.13	0.00
Capital Lease Obligations	5.08	3.64	2.86	1.21	11	9.88
Other Noncurrent Operating Liabilities	3.83	-	-	-	-	0.00
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	-431	138	90	160	281	276
Total Preferred & Common Equity	-431	138	90	160	281	276
Preferred Stock	-	-	0.00	0.00	0.00	0.00
Total Common Equity	-431	138	90	160	281	276
Common Stock	0.00	618	636	755	903	937
Retained Earnings	-431	-479	-546	-595	-622	-661
Accumulated Other Comprehensive Income / (Loss)	-0.00	-0.02	-0.10	-0.01	0.17	0.05

This table presents RxSight's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q1 2023	Q2 2023	Q3 2023	Q1 2024	Q2 2024	Q3 2024	Q1 2025	Q2 2025	Q3 2025	Q1 2026
Period end date	9/30/2022	3/31/2023	6/30/2023	9/30/2023	3/31/2024	6/30/2024	9/30/2024	3/31/2025	6/30/2025	9/30/2025	3/31/2026
Total Assets	156	203	195	182	183	305	310	313	309	309	304
Total Current Assets	139	188	180	168	169	281	287	288	284	284	279
Cash & Equivalents	8.91	11	8.75	9.86	33	24	17	28	40	30	18
Short-Term Investments	104	143	138	122	93	209	220	201	187	198	200
Accounts Receivable	9.02	13	13	15	22	26	25	31	28	24	22
Inventories, net	15	18	18	19	19	19	22	24	25	29	35
Prepaid Expenses	1.97	2.99	2.11	1.90	2.96	2.77	2.61	4.54	3.26	3.26	4.03
Plant, Property, & Equipment, net	11	9.80	11	10	12	12	12	13	13	13	13
Total Noncurrent Assets	5.92	5.06	4.28	3.64	2.99	12	11	12	12	12	12
Other Noncurrent Operating Assets	5.92	5.06	4.28	3.64	2.99	12	11	12	12	12	12
Total Liabilities & Shareholders' Equity	156	203	195	182	183	305	310	313	309	309	304
Total Liabilities	60	58	38	20	19	30	33	34	31	33	37
Total Current Liabilities	16	15	17	19	18	20	23	23	20	22	27
Accounts Payable	4.17	3.72	4.00	4.11	5.06	5.10	4.58	7.11	3.35	3.38	7.12
Accrued Expenses	10	9.18	11	13	12	14	17	15	16	18	19
Other Current Liabilities	1.95	1.98	1.98	1.98	1.61	0.74	0.73	1.06	1.10	1.29	1.50
Total Noncurrent Liabilities	43	43	22	1.43	0.91	11	11	11	11	10	9.32
Long-Term Debt	40	40	20	0.08	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Capital Lease Obligations	3.35	2.34	1.84	1.35	0.91	11	11	11	11	10	9.32
Other Noncurrent Operating Liabilities	-	-	-	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	96	145	157	161	164	275	277	279	278	276	267
Total Preferred & Common Equity	96	145	157	161	164	275	277	279	278	276	267
Preferred Stock	0.00	-	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	96	145	157	161	164	275	277	279	278	276	267
Common Stock	627	704	730	747	768	885	893	910	920	928	944
Retained Earnings	-530	-559	-573	-585	-604	-610	-616	-630	-642	-652	-677
Accumulated Other Comprehensive Income / (Loss)	-0.14	-0.01	-0.07	-0.06	-0.05	-0.12	0.52	0.02	-0.12	0.06	-0.07

This table displays calculated financial ratios and metrics derived from RxSight's official financial filings.

Metric	2020	2021	2022	2023	2024	2025
Period end date	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
DEI Shares Outstanding	0.00	27,353,915.00	-	-	-	41,116,640.00
DEI Adjusted Shares Outstanding	0.00	27,353,915.00	-	-	-	41,116,640.00
DEI Earnings Per Adjusted Shares Outstanding	0.00	-2.16	-	-	-	-0.95
Growth Metrics	-	-	-	-	-	-
Revenue Growth	0.00%	53.92%	116.90%	81.77%	57.09%	-3.89%
EBITDA Growth	0.00%	-263.37%	-17.82%	14.09%	18.32%	-26.46%
EBIT Growth	0.00%	-301.11%	-14.08%	20.90%	26.41%	-30.75%
NOPAT Growth	0.00%	-4.56%	-19.95%	20.90%	26.41%	-30.75%
Net Income Growth	0.00%	-276.57%	-37.11%	27.19%	43.52%	-41.85%
EPS Growth	0.00%	-2,480.00%	32.49%	41.49%	49.65%	-33.80%
Operating Cash Flow Growth	0.00%	-27.00%	-31.63%	29.32%	59.26%	8.47%
Free Cash Flow Firm Growth	0.00%	0.00%	-14.30%	13.71%	-10.38%	23.71%
Invested Capital Growth	0.00%	37.10%	21.57%	27.06%	60.93%	3.55%
Revenue Q/Q Growth	0.00%	0.00%	18.53%	16.31%	9.07%	-5.35%
EBITDA Q/Q Growth	0.00%	0.00%	13.40%	6.04%	1.42%	-3.05%
EBIT Q/Q Growth	0.00%	0.00%	13.79%	7.63%	5.69%	-5.95%
NOPAT Q/Q Growth	0.00%	0.00%	-0.52%	7.63%	5.69%	-5.95%
Net Income Q/Q Growth	0.00%	0.00%	0.18%	11.69%	10.55%	-9.00%
EPS Q/Q Growth	0.00%	0.00%	-97.54%	18.02%	12.35%	-9.20%
Operating Cash Flow Q/Q Growth	0.00%	-1.12%	-9.55%	11.78%	19.25%	16.85%
Free Cash Flow Firm Q/Q Growth	0.00%	0.00%	0.00%	0.19%	0.51%	10.42%
Invested Capital Q/Q Growth	0.00%	0.00%	2.35%	11.08%	9.37%	-2.20%
Profitability Metrics	-	-	-	-	-	-
Gross Margin	11.62%	19.99%	43.52%	60.36%	70.71%	76.60%
EBITDA Margin	212.90%	-225.97%	-122.74%	-58.01%	-30.17%	-39.74%
Operating Margin	-241.26%	-233.64%	-129.21%	-56.23%	-26.34%	-35.84%
EBIT Margin	188.03%	-245.67%	-129.21%	-56.23%	-26.34%	-35.84%
Profit (Net Income) Margin	187.87%	-215.50%	-136.22%	-54.57%	-19.62%	-28.96%
Tax Burden Percent	99.79%	100.02%	100.01%	100.04%	100.18%	100.17%
Interest Burden Percent	100.12%	87.71%	105.42%	97.01%	74.35%	80.67%
Effective Tax Rate	0.21%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	-217.15%	-191.52%	-179.31%	-113.85%	-57.38%	-59.76%
ROIC Less NNEP Spread (ROIC-NNEP)	-376.44%	-176.42%	-154.20%	-99.49%	-56.44%	-57.41%
Return on Net Nonoperating Assets (RNNOA)	266.59%	141.33%	120.79%	75.00%	44.95%	45.77%
Return on Equity (ROE)	49.44%	-50.19%	-58.52%	-38.85%	-12.43%	-13.99%
Cash Return on Invested Capital (CROIC)	0.00%	-222.82%	-198.78%	-137.68%	-104.08%	-63.25%
Operating Return on Assets (OROA)	27.41%	-37.84%	-36.93%	-30.11%	-14.71%	-15.29%
Return on Assets (ROA)	27.39%	-33.19%	-38.94%	-29.22%	-10.96%	-12.36%
Return on Common Equity (ROCE)	-381.74%	75.63%	-58.52%	-38.85%	-12.43%	-13.99%
Return on Equity Simple (ROE_SIMPLE)	-6.40%	-35.22%	-74.25%	-30.31%	-9.76%	0.00%
Net Operating Profit after Tax (NOPAT)	-35	-37	-44	-35	-26	-34
NOPAT Margin	-240.76%	-163.55%	-90.45%	-39.36%	-18.44%	-25.08%
Net Nonoperating Expense Percent (NNEP)	159.29%	-15.10%	-25.11%	-14.36%	-0.94%	-2.35%
Return On Investment Capital (ROIC_SIMPLE)	-	-	-33.34%	-21.69%	-8.82%	-11.81%
Cost of Revenue to Revenue	88.38%	80.01%	56.48%	39.64%	29.29%	23.40%
SG&A Expenses to Revenue	103.39%	145.20%	119.71%	83.97%	72.49%	83.77%
R&D to Revenue	149.43%	108.44%	53.02%	32.61%	24.56%	28.67%
Operating Expenses to Revenue	252.78%	253.64%	172.73%	116.58%	97.05%	112.43%
Earnings before Interest and Taxes (EBIT)	28	-56	-63	-50	-37	-48
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	31	-51	-60	-52	-42	-53
Valuation Ratios	-	-	-	-	-	-
Price to Book Value (P/BV)	0.00	2.23	3.91	9.02	4.93	1.55
Price to Tangible Book Value (P/TBV)	0.00	2.23	3.91	9.02	4.93	1.55
Price to Revenue (P/Rev)	8.01	13.62	7.17	16.23	9.90	3.19
Price to Earnings (P/E)	34.94	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	2.86%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	34.69	8.60	10.63	38.30	20.91	3.66
Enterprise Value to Revenue (EV/Rev)	38.46	8.49	5.89	14.82	8.29	1.56
Enterprise Value to EBITDA (EV/EBITDA)	18.06	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	20.45	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-
Debt to Equity	0.53	0.31	0.48	0.01	0.04	0.04
Long-Term Debt to Equity	0.53	0.31	0.48	0.01	0.04	0.04
Financial Leverage	-0.71	-0.80	-0.78	-0.75	-0.80	-0.80
Leverage Ratio	1.81	1.51	1.50	1.33	1.13	1.13
Compound Leverage Factor	1.81	1.33	1.58	1.29	0.84	0.91
Debt to Total Capital	34.58%	23.89%	32.37%	0.79%	3.91%	3.46%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	34.58%	23.89%	32.37%	0.79%	3.91%	3.46%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	570.52%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	-505.10%	76.11%	67.63%	99.21%	96.09%	96.54%
Debt to EBITDA	0.94	-0.85	-0.72	-0.02	-0.27	-0.18
Net Debt to EBITDA	-1.26	2.27	1.04	2.44	5.35	4.08
Long-Term Debt to EBITDA	0.94	-0.85	-0.72	-0.02	-0.27	-0.18
Debt to NOPAT	-0.83	-1.17	-0.97	-0.04	-0.44	-0.29
Net Debt to NOPAT	1.12	3.14	1.42	3.59	8.75	6.47
Long-Term Debt to NOPAT	-0.83	-1.17	-0.97	-0.04	-0.44	-0.29
Altman Z-Score	-2.53	0.10	-1.72	35.09	20.61	5.07
Noncontrolling Interest Sharing Ratio	872.07%	250.69%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-
Current Ratio	7.03	15.92	7.81	8.06	11.36	10.95
Quick Ratio	6.19	14.82	6.77	7.05	10.33	9.58
Cash Flow Metrics	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	0.00	-43	-49	-42	-47	-36
Operating Cash Flow to CapEx	-1,388.13%	-2,304.54%	-2,459.26%	-864.00%	-311.51%	-404.99%
Free Cash Flow to Firm to Interest Expense	0.00	-11.68	-9.93	-8.35	-2,228.55	-1,879.09
Operating Cash Flow to Interest Expense	-69.03	-12.14	-11.90	-8.19	-806.95	-816.37
Operating Cash Flow Less CapEx to Interest Expense	-74.00	-12.67	-12.38	-9.14	-1,066.00	-1,017.95
Efficiency Ratios	-	-	-	-	-	-
Asset Turnover	0.15	0.15	0.29	0.54	0.56	0.43
Accounts Receivable Turnover	5.12	5.85	6.20	5.70	5.56	5.03
Inventory Turnover	1.57	2.22	2.42	2.19	2.08	1.18
Fixed Asset Turnover	1.10	1.84	4.59	8.49	12.03	10.56
Accounts Payable Turnover	11.44	12.81	12.92	10.94	9.75	6.40
Days Sales Outstanding (DSO)	71.24	62.42	58.91	64.00	65.64	72.51
Days Inventory Outstanding (DIO)	233.19	164.77	150.78	166.71	175.58	310.65
Days Payable Outstanding (DPO)	31.91	28.50	28.25	33.38	37.44	57.06
Cash Conversion Cycle (CCC)	272.52	198.69	181.44	197.33	203.79	326.10
Capital & Investment Metrics	-	-	-	-	-	-
Invested Capital	16	22	27	34	55	57
Invested Capital Turnover	0.90	1.17	1.98	2.89	3.11	2.38
Increase / (Decrease) in Invested Capital	0.00	6.04	4.81	7.34	21	1.97
Enterprise Value (EV)	564	192	288	1,320	1,160	210
Market Capitalization	118	308	351	1,446	1,386	428
Book Value per Share	($116.15)	$5.05	$3.24	$4.47	$6.98	$6.70
Tangible Book Value per Share	($116.15)	$5.05	$3.24	$4.47	$6.98	$6.70
Total Capital	85	182	133	162	293	286
Total Debt	29	43	43	1.29	11	9.88
Total Long-Term Debt	29	43	43	1.29	11	9.88
Net Debt	-39	-116	-63	-126	-226	-218
Capital Expenditures (CapEx)	2.54	1.94	2.39	4.81	5.44	3.83
Debt-free, Cash-free Net Working Capital (DFCFNWC)	0.93	5.89	12	20	31	33
Debt-free Net Working Capital (DFNWC)	70	165	117	148	268	261
Net Working Capital (NWC)	70	165	117	148	268	261
Net Nonoperating Expense (NNE)	-63	12	22	14	1.65	5.21
Net Nonoperating Obligations (NNO)	-39	-116	-63	-126	-226	-218
Total Depreciation and Amortization (D&A)	3.65	4.45	3.17	-1.59	-5.35	-5.25
Debt-free, Cash-free Net Working Capital to Revenue	6.30%	26.05%	23.50%	22.81%	21.96%	24.60%
Debt-free Net Working Capital to Revenue	476.22%	731.28%	239.40%	165.59%	191.49%	194.24%
Net Working Capital to Revenue	476.22%	731.28%	239.40%	165.59%	191.49%	194.24%
Earnings Adjustments	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.00	($3.57)	($2.41)	($1.41)	($0.71)	($0.95)
Adjusted Weighted Average Basic Shares Outstanding	0.00	13.63M	27.66M	34.46M	38.87M	40.85M
Adjusted Diluted Earnings per Share	$0.00	($3.57)	($2.41)	($1.41)	($0.71)	($0.95)
Adjusted Weighted Average Diluted Shares Outstanding	0.00	13.63M	27.66M	34.46M	38.87M	40.85M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	0.00	0.00	33.78M	36.99M	40.49M	41.27M
Normalized Net Operating Profit after Tax (NOPAT)	-35	-37	-44	-35	-26	-34
Normalized NOPAT Margin	-240.81%	-163.55%	-90.45%	-39.36%	-18.44%	-25.08%
Pre Tax Income Margin	188.25%	-215.47%	-136.20%	-54.55%	-19.59%	-28.91%
Debt Service Ratios	-	-	-	-	-	-
EBIT to Interest Expense	54.12	-15.07	-12.80	-9.87	-1,755.14	-2,536.37
NOPAT to Interest Expense	-69.29	-10.04	-8.96	-6.91	-1,228.60	-1,775.46
EBIT Less CapEx to Interest Expense	49.14	-15.60	-13.29	-10.81	-2,014.19	-2,737.95
NOPAT Less CapEx to Interest Expense	-74.26	-10.56	-9.45	-7.85	-1,487.65	-1,977.04
Payout Ratios	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	-0.88%	-1.28%	-2.80%	0.00%

This table displays calculated financial ratios and metrics derived from RxSight's official financial filings.

Metric	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Period end date	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025	3/31/2026
DEI Shares Outstanding	-	-	-	-	-	-	40,490,542.00	40,636,981.00	40,915,963.00	41,116,640.00	41,266,335.00
DEI Adjusted Shares Outstanding	-	-	-	-	-	-	40,490,542.00	40,636,981.00	40,915,963.00	41,116,640.00	41,266,335.00
DEI Earnings Per Adjusted Shares Outstanding	-	-	-	-	-	-	-0.20	-0.29	-0.24	-0.22	-0.38
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	75.97%	77.64%	68.75%	67.65%	59.08%	40.71%	28.41%	-3.58%	-14.09%	-18.92%	-18.48%
EBITDA Growth	14.82%	22.66%	16.49%	32.25%	16.30%	5.38%	-11.46%	-60.20%	-24.06%	-14.23%	-53.24%
EBIT Growth	21.59%	27.61%	18.53%	38.84%	26.26%	20.48%	-0.04%	-68.04%	-32.00%	-31.37%	-67.03%
NOPAT Growth	21.59%	27.61%	18.53%	38.84%	26.26%	20.48%	-0.04%	-68.04%	-32.00%	-31.37%	-67.03%
Net Income Growth	26.18%	41.21%	31.12%	55.96%	48.95%	35.29%	10.00%	-93.88%	-54.88%	-54.13%	-93.94%
EPS Growth	42.62%	56.36%	40.48%	60.00%	54.29%	41.67%	20.00%	-81.25%	-50.00%	-57.14%	-90.00%
Operating Cash Flow Growth	47.45%	40.08%	47.60%	46.63%	108.14%	48.68%	5.12%	-8.67%	-282.62%	73.80%	-23.31%
Free Cash Flow Firm Growth	-16.74%	2.42%	34.90%	-67.23%	-96.84%	-81.04%	-118.74%	31.64%	36.73%	63.37%	64.58%
Invested Capital Growth	17.07%	27.06%	17.10%	66.43%	63.45%	60.93%	54.40%	16.23%	15.81%	3.55%	-3.65%
Revenue Q/Q Growth	6.67%	28.74%	3.26%	18.21%	1.22%	13.88%	-5.77%	-11.24%	-9.80%	7.47%	-5.26%
EBITDA Q/Q Growth	8.33%	12.54%	2.72%	13.13%	-13.25%	1.12%	-14.07%	-24.85%	12.30%	8.55%	-53.03%
EBIT Q/Q Growth	8.17%	13.28%	1.67%	21.90%	-10.72%	6.47%	-23.70%	-31.19%	13.03%	6.91%	-57.28%
NOPAT Q/Q Growth	8.17%	13.28%	1.67%	21.90%	-10.72%	6.47%	-23.70%	-31.19%	13.03%	6.91%	-57.28%
Net Income Q/Q Growth	10.06%	26.08%	0.84%	33.20%	-4.26%	6.31%	-37.93%	-43.91%	16.71%	6.76%	-73.56%
EPS Q/Q Growth	12.50%	31.43%	-4.17%	36.00%	0.00%	12.50%	-42.86%	-45.00%	17.24%	8.33%	-72.73%
Operating Cash Flow Q/Q Growth	-5.78%	-4.00%	-12.14%	56.74%	116.14%	-755.38%	-107.32%	50.45%	72.87%	5.98%	-875.90%
Free Cash Flow Firm Q/Q Growth	17.21%	-12.46%	11.39%	-102.70%	2.55%	-3.43%	-7.07%	36.65%	9.82%	40.12%	-3.55%
Invested Capital Q/Q Growth	-1.83%	11.08%	14.56%	33.21%	-3.59%	9.37%	9.91%	0.28%	-3.94%	-2.20%	2.27%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	61.85%	61.77%	70.09%	69.51%	71.42%	71.59%	74.76%	74.89%	79.85%	77.48%	76.06%
EBITDA Margin	-58.43%	-39.69%	-37.39%	-27.48%	-30.74%	-26.69%	-32.46%	-45.66%	-44.39%	-37.77%	-61.01%
Operating Margin	-56.36%	-37.97%	-36.15%	-23.89%	-26.13%	-21.46%	-28.17%	-41.63%	-40.14%	-34.77%	-57.71%
EBIT Margin	-56.36%	-37.97%	-36.15%	-23.89%	-26.13%	-21.46%	-28.17%	-41.63%	-40.14%	-34.77%	-57.71%
Profit (Net Income) Margin	-55.93%	-32.11%	-30.83%	-17.42%	-17.95%	-14.77%	-21.61%	-35.04%	-32.35%	-28.07%	-51.42%
Tax Burden Percent	100.10%	99.80%	100.10%	100.26%	100.21%	100.20%	100.22%	100.27%	100.10%	100.07%	100.04%
Interest Burden Percent	99.13%	84.74%	85.20%	72.76%	68.56%	68.68%	76.56%	83.94%	80.52%	80.68%	89.06%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	-105.05%	-76.88%	-69.91%	-45.74%	-57.41%	-46.74%	-58.23%	-75.36%	-72.96%	-57.98%	-86.05%
ROIC Less NNEP Spread (ROIC-NNEP)	-101.39%	-75.20%	-68.53%	-45.60%	-57.48%	-46.80%	-57.81%	-74.46%	-72.38%	-57.43%	-84.45%
Return on Net Nonoperating Assets (RNNOA)	78.73%	56.70%	52.29%	36.72%	46.77%	37.27%	44.71%	59.15%	58.06%	45.79%	65.96%
Return on Equity (ROE)	-26.32%	-20.18%	-17.62%	-9.02%	-10.64%	-9.47%	-13.52%	-16.21%	-14.90%	-12.19%	-20.09%
Cash Return on Invested Capital (CROIC)	-147.68%	-137.68%	-106.90%	-120.31%	-115.10%	-104.08%	-94.15%	-67.37%	-72.83%	-63.25%	-61.02%
Operating Return on Assets (OROA)	-25.58%	-20.33%	-18.95%	-10.99%	-13.62%	-11.98%	-16.84%	-19.93%	-18.43%	-14.83%	-23.85%
Return on Assets (ROA)	-25.38%	-17.19%	-16.17%	-8.02%	-9.35%	-8.25%	-12.92%	-16.77%	-14.85%	-11.98%	-21.24%
Return on Common Equity (ROCE)	-26.32%	-20.18%	-17.62%	-9.02%	-10.64%	-9.47%	-13.52%	-16.21%	-14.90%	-12.19%	-20.09%
Return on Equity Simple (ROE_SIMPLE)	-34.09%	0.00%	-27.14%	-13.36%	-11.07%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Net Operating Profit after Tax (NOPAT)	-8.76	-7.60	-7.47	-5.83	-6.46	-6.04	-7.47	-9.80	-8.52	-7.94	-12
NOPAT Margin	-39.45%	-26.58%	-25.31%	-16.72%	-18.29%	-15.02%	-19.72%	-29.14%	-28.10%	-24.34%	-40.40%
Net Nonoperating Expense Percent (NNEP)	-3.66%	-1.68%	-1.38%	-0.14%	0.07%	0.06%	-0.42%	-0.90%	-0.58%	-0.55%	-1.59%
Return On Investment Capital (ROIC_SIMPLE)	-	-4.70%	-	-	-	-2.06%	-2.57%	-3.40%	-2.98%	-2.78%	-4.51%
Cost of Revenue to Revenue	38.15%	38.23%	29.91%	30.49%	28.58%	28.41%	25.24%	25.11%	20.15%	22.52%	23.94%
SG&A Expenses to Revenue	86.23%	74.05%	79.03%	69.63%	72.52%	70.15%	75.57%	86.14%	90.13%	84.93%	103.11%
R&D to Revenue	31.99%	25.69%	27.21%	23.77%	25.03%	22.90%	27.36%	30.37%	29.86%	27.31%	30.66%
Operating Expenses to Revenue	118.22%	99.74%	106.24%	93.40%	97.54%	93.04%	102.92%	116.52%	119.99%	112.24%	133.77%
Earnings before Interest and Taxes (EBIT)	-13	-11	-11	-8.33	-9.23	-8.63	-11	-14	-12	-11	-18
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-13	-11	-11	-9.59	-11	-11	-12	-15	-13	-12	-19
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	6.16	9.02	11.64	8.13	7.07	4.93	3.66	1.90	1.33	1.55	0.95
Price to Tangible Book Value (P/TBV)	6.16	9.02	11.64	8.13	7.07	4.93	3.66	1.90	1.33	1.55	0.95
Price to Revenue (P/Rev)	12.98	16.23	18.87	19.43	15.29	9.90	6.89	3.59	2.59	3.19	1.99
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	27.84	38.30	45.17	38.32	34.21	20.91	13.19	5.09	2.56	3.66	0.78
Enterprise Value to Revenue (EV/Rev)	11.28	14.82	17.64	17.50	13.52	8.29	5.42	2.12	1.06	1.56	0.36
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.01	0.01	0.01	0.04	0.04	0.04	0.04	0.04	0.04	0.04	0.03
Long-Term Debt to Equity	0.01	0.01	0.01	0.04	0.04	0.04	0.04	0.04	0.04	0.04	0.03
Financial Leverage	-0.78	-0.75	-0.76	-0.81	-0.81	-0.80	-0.77	-0.79	-0.80	-0.80	-0.78
Leverage Ratio	1.31	1.33	1.25	1.16	1.12	1.13	1.12	1.11	1.12	1.13	1.13
Compound Leverage Factor	1.30	1.13	1.06	0.84	0.77	0.78	0.86	0.93	0.90	0.91	1.01
Debt to Total Capital	0.88%	0.79%	0.55%	3.73%	3.67%	3.91%	3.78%	3.68%	3.59%	3.46%	3.37%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.88%	0.79%	0.55%	3.73%	3.67%	3.91%	3.78%	3.68%	3.59%	3.46%	3.37%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	99.12%	99.21%	99.45%	96.27%	96.33%	96.09%	96.22%	96.32%	96.41%	96.54%	96.63%
Debt to EBITDA	-0.03	-0.02	-0.02	-0.24	-0.25	-0.27	-0.25	-0.22	-0.20	-0.18	-0.16
Net Debt to EBITDA	2.37	2.44	2.51	4.95	5.29	5.35	5.02	4.40	4.19	4.08	3.48
Long-Term Debt to EBITDA	-0.03	-0.02	-0.02	-0.24	-0.25	-0.27	-0.25	-0.22	-0.20	-0.18	-0.16
Debt to NOPAT	-0.04	-0.04	-0.03	-0.36	-0.39	-0.44	-0.43	-0.36	-0.32	-0.29	-0.24
Net Debt to NOPAT	3.44	3.59	3.73	7.51	8.28	8.75	8.46	7.28	6.82	6.47	5.38
Long-Term Debt to NOPAT	-0.04	-0.04	-0.03	-0.36	-0.39	-0.44	-0.43	-0.36	-0.32	-0.29	-0.24
Altman Z-Score	25.95	35.80	56.24	42.85	34.00	20.90	16.75	8.67	5.17	5.46	2.26
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	8.87	8.06	9.20	14.33	12.67	11.36	12.68	13.93	12.74	10.95	10.20
Quick Ratio	7.77	7.05	8.02	13.20	11.60	10.33	11.45	12.54	11.29	9.58	8.78
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-13	-15	-13	-27	-26	-27	-29	-18	-17	-9.90	-10
Operating Cash Flow to CapEx	-1,222.36%	-521.75%	-473.26%	-264.41%	58.93%	-502.95%	-1,536.00%	-284.71%	-204.30%	-98.15%	-1,434.91%
Free Cash Flow to Firm to Interest Expense	-8.11	-4,978.57	-2,205.83	-4,471.18	-5,228.64	-6,759.83	-4,825.13	-3,668.02	-4,134.90	-2,476.05	-3,418.43
Operating Cash Flow to Interest Expense	-4.88	-2,767.00	-1,551.50	-671.17	130.00	-1,065.00	-1,472.00	-875.20	-296.75	-279.00	-3,630.33
Operating Cash Flow Less CapEx to Interest Expense	-5.27	-3,297.33	-1,879.33	-925.00	-90.60	-1,276.75	-1,567.83	-1,182.60	-442.00	-563.25	-3,883.33
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.45	0.54	0.52	0.46	0.52	0.56	0.60	0.48	0.46	0.43	0.41
Accounts Receivable Turnover	6.31	5.70	5.91	5.90	6.32	5.56	5.65	5.47	5.74	5.03	4.77
Inventory Turnover	1.93	2.19	2.01	2.08	1.99	2.08	1.97	1.78	1.40	1.18	1.00
Fixed Asset Turnover	7.34	8.49	9.44	10.03	11.40	12.03	12.27	11.44	11.22	10.56	9.89
Accounts Payable Turnover	7.99	10.94	8.44	8.55	9.32	9.75	6.86	9.36	8.93	6.40	4.12
Days Sales Outstanding (DSO)	57.82	64.00	61.77	61.82	57.77	65.64	64.61	66.74	63.60	72.51	76.45
Days Inventory Outstanding (DIO)	189.18	166.71	181.27	175.60	183.01	175.58	184.91	205.45	259.86	310.65	364.03
Days Payable Outstanding (DPO)	45.70	33.38	43.26	42.70	39.16	37.44	53.22	38.98	40.85	57.06	88.67
Cash Conversion Cycle (CCC)	201.29	197.33	199.78	194.72	201.63	203.79	196.30	233.21	282.62	326.10	351.82
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	31	34	39	53	51	55	61	61	59	57	59
Invested Capital Turnover	2.66	2.89	2.76	2.74	3.14	3.11	2.95	2.59	2.60	2.38	2.13
Increase / (Decrease) in Invested Capital	4.52	7.34	5.77	21	20	21	21	8.54	8.02	1.97	-2.23
Enterprise Value (EV)	864	1,320	1,783	2,015	1,735	1,160	804	311	151	210	46
Market Capitalization	994	1,446	1,908	2,238	1,962	1,386	1,022	528	368	428	254
Book Value per Share	$4.53	$4.47	$4.43	$7.40	$6.99	$6.98	$6.90	$6.84	$6.74	$6.70	$6.48
Tangible Book Value per Share	$4.53	$4.47	$4.43	$7.40	$6.99	$6.98	$6.90	$6.84	$6.74	$6.70	$6.48
Total Capital	163	162	165	286	288	293	290	289	286	286	277
Total Debt	1.43	1.29	0.91	11	11	11	11	11	10	9.88	9.32
Total Long-Term Debt	1.43	1.29	0.91	11	11	11	11	11	10	9.88	9.32
Net Debt	-130	-126	-124	-223	-227	-226	-218	-217	-217	-218	-209
Capital Expenditures (CapEx)	0.65	1.59	1.97	1.52	1.10	0.85	0.58	1.54	0.58	1.14	0.76
Debt-free, Cash-free Net Working Capital (DFCFNWC)	17	20	25	28	27	31	36	36	34	33	34
Debt-free Net Working Capital (DFNWC)	149	148	150	262	264	268	266	263	262	261	252
Net Working Capital (NWC)	149	148	150	262	264	268	266	263	262	261	252
Net Nonoperating Expense (NNE)	3.66	1.58	1.63	0.25	-0.12	-0.10	0.72	1.98	1.29	1.22	3.40
Net Nonoperating Obligations (NNO)	-130	-126	-124	-223	-227	-226	-218	-217	-217	-218	-209
Total Depreciation and Amortization (D&A)	-0.46	-0.49	-0.37	-1.25	-1.63	-2.11	-1.63	-1.35	-1.29	-0.98	-1.02
Debt-free, Cash-free Net Working Capital to Revenue	22.36%	22.81%	24.61%	24.59%	21.05%	21.96%	24.50%	24.48%	23.98%	24.60%	26.65%
Debt-free Net Working Capital to Revenue	194.56%	165.59%	148.60%	227.13%	205.88%	191.49%	179.13%	179.17%	184.10%	194.24%	197.56%
Net Working Capital to Revenue	194.56%	165.59%	148.60%	227.13%	205.88%	191.49%	179.13%	179.17%	184.10%	194.24%	197.56%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($0.35)	($0.24)	($0.25)	($0.16)	($0.16)	($0.14)	($0.20)	($0.29)	($0.24)	($0.22)	($0.38)
Adjusted Weighted Average Basic Shares Outstanding	35.66M	34.46M	36.84M	38.46M	39.79M	38.87M	40.51M	40.74M	40.97M	40.85M	41.31M
Adjusted Diluted Earnings per Share	($0.35)	($0.24)	($0.25)	($0.16)	($0.16)	($0.14)	($0.20)	($0.29)	($0.24)	($0.22)	($0.38)
Adjusted Weighted Average Diluted Shares Outstanding	35.66M	34.46M	36.84M	38.46M	39.79M	38.87M	40.51M	40.74M	40.97M	40.85M	41.31M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	35.86M	36.99M	37.20M	39.68M	40.30M	40.49M	40.64M	40.92M	41.12M	41.27M	41.40M
Normalized Net Operating Profit after Tax (NOPAT)	-8.76	-7.60	-7.47	-5.83	-6.46	-6.04	-7.47	-9.80	-8.52	-7.94	-12
Normalized NOPAT Margin	-39.45%	-26.58%	-25.31%	-16.72%	-18.29%	-15.02%	-19.72%	-29.14%	-28.10%	-24.34%	-40.40%
Pre Tax Income Margin	-55.87%	-32.17%	-30.80%	-17.38%	-17.91%	-14.74%	-21.56%	-34.94%	-32.32%	-28.05%	-51.40%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	-7.64	-3,617.00	-1,778.33	-1,388.83	-1,845.20	-2,157.25	-1,779.00	-2,800.60	-3,044.50	-2,834.00	-5,943.00
NOPAT to Interest Expense	-5.35	-2,531.90	-1,244.83	-972.18	-1,291.64	-1,510.08	-1,245.30	-1,960.42	-2,131.15	-1,983.80	-4,160.10
EBIT Less CapEx to Interest Expense	-8.04	-4,147.33	-2,106.17	-1,642.67	-2,065.80	-2,369.00	-1,874.83	-3,108.00	-3,189.75	-3,118.25	-6,196.00
NOPAT Less CapEx to Interest Expense	-5.75	-3,062.23	-1,572.67	-1,226.02	-1,512.24	-1,721.83	-1,341.13	-2,267.82	-2,276.40	-2,268.05	-4,413.10
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	-1.71%	-1.28%	-0.88%	-1.08%	-2.42%	-2.80%	-2.89%	-1.21%	0.00%	0.00%	0.00%

Financials Breakdown Chart

Key Financial Trends

RxSight’s latest quarter shows a company with strong liquidity, but continuing operating losses and rising inventory pressure. In Q1 2026, revenue was up from the prior quarter, while cash on the balance sheet remains substantial thanks to a large investment portfolio. However, the business is still not profitable, and operating cash flow was negative despite better other income from investments.

Revenue increased sequentially to $30.9 million in Q1 2026 from $32.6 million in Q4 2025, but more importantly it remains well above the company’s 2024 and early 2025 levels.
Gross profit was solid at $23.5 million in Q1 2026, with gross margin of about 76%, showing the core product still generates strong unit economics.
RxSight ended Q1 2026 with $17.6 million in cash and equivalents plus $200.3 million in short-term investments, giving it a large liquidity cushion.
Total current assets were $279.2 million versus current liabilities of only $27.4 million, indicating a very strong near-term liquidity position.
Interest and investment income of $1.95 million helped offset operating losses in Q1 2026, and the company’s investment balance continues to support earnings below the operating line.
Q1 2026 operating revenue of $30.9 million was lower than Q1 2025’s $37.9 million, suggesting year-over-year growth has not yet stabilized.
The company has no long-term debt, which reduces financial risk, although it does carry $9.3 million in capital lease obligations.
Share count remains elevated at roughly 41.3 million diluted weighted average shares in Q1 2026, so dilution remains a consideration for per-share results.
Inventory climbed to $34.9 million in Q1 2026 from $25.1 million in Q2 2025, which may reflect stocking for future demand but also ties up working capital.
RxSight reported a net loss of $15.9 million in Q1 2026, essentially unchanged from Q4 2025 and still deeply negative.
Operating cash flow was negative $10.9 million in Q1 2026, showing the business is still burning cash from core operations.
Selling, general and administrative expense was $31.9 million, which exceeded gross profit and kept operating income negative.
Research and development spending of $9.5 million and SG&A together drove total operating expenses to $41.3 million, outpacing revenue growth.
Retained earnings remain deeply negative at $(676.9) million, highlighting the long history of cumulative losses.

Longer-term trend: RxSight has made a meaningful improvement in revenue since 2023, when quarterly revenue was often in the low-to-mid teens or low $20 millions. By 2024 and 2025, revenue moved into the high $20 millions to low $40 millions. That said, expenses have also risen, so the company still has not translated growth into profitability.

Bottom line: RxSight looks financially stable for now because of its large cash and investment balance, but investors should focus on whether revenue can reaccelerate and whether operating losses start narrowing on a sustained basis. Until then, the stock remains a balance between promising growth potential and continued cash burn.

07/05/26 02:28 PM ETAI Generated. May Contain Errors.

RxSight Financials - Frequently Asked Questions

According to the most recent income statement we have on file, RxSight's financial year ends in December. Their financial year 2025 ended on December 31, 2025.

RxSight's net income appears to be on an upward trend, with a most recent value of -$38.94 million in 2025, falling from $27.58 million in 2020. The previous period was -$27.46 million in 2024. View RxSight's forecast to see where analysts expect RxSight to go next.

RxSight's total operating income in 2025 was -$48.19 million, based on the following breakdown:

Total Gross Profit: $103.01 million
Total Operating Expenses: $151.20 million

Over the last 5 years, RxSight's total revenue changed from $14.68 million in 2020 to $134.48 million in 2025, a change of 816.2%.

RxSight's total liabilities were at $36.13 million at the end of 2025, a 3.2% decrease from 2024, and a 19.5% decrease since 2020.

In the past 5 years, RxSight's cash and equivalents has ranged from $9.69 million in 2023 to $24.36 million in 2021, and is currently $19.95 million as of their latest financial filing in 2025.

Over the last 5 years, RxSight's book value per share changed from -116.15 in 2020 to 6.70 in 2025, a change of -105.8%.

Related Companies

Financial statements for NASDAQ:RXST last updated on 7/2/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

RxSight (RXST) Financials

Financials Breakdown Chart

Key Financial Trends

RxSight Financials - Frequently Asked Questions

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

RxSight (RXST) Financials

Annual Income Statements for RxSight

Quarterly Income Statements for RxSight

Annual Cash Flow Statements for RxSight

Quarterly Cash Flow Statements for RxSight

Annual Balance Sheets for RxSight

Quarterly Balance Sheets for RxSight

Annual Metrics And Ratios for RxSight

Quarterly Metrics And Ratios for RxSight

Financials Breakdown Chart

Key Financial Trends

RxSight Financials - Frequently Asked Questions

When does RxSight's fiscal year end?

How has RxSight's net income changed over the last 5 years?

What is RxSight's operating income?

How has RxSight's revenue changed over the last 5 years?

How much debt does RxSight have?

How much cash does RxSight have?

How has RxSight's book value per share changed over the last 5 years?

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools